Pfizer Inc. (NYSE:PFE) Shares Sold by CFS Investment Advisory Services LLC

CFS Investment Advisory Services LLC trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 50.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,049 shares of the biopharmaceutical company's stock after selling 24,319 shares during the quarter. CFS Investment Advisory Services LLC's holdings in Pfizer were worth $696,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Charles Schwab Investment Management Inc. raised its position in Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares during the period. Marshall Wace LLP raised its holdings in shares of Pfizer by 279.3% during the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock valued at $150,481,000 after buying an additional 8,378,173 shares during the period. Swedbank AB acquired a new position in Pfizer during the 1st quarter worth approximately $172,902,000. International Assets Investment Management LLC purchased a new position in Pfizer in the 3rd quarter worth approximately $146,481,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company's stock valued at $211,737,000 after acquiring an additional 4,546,809 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Daiwa America raised shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price target on the stock. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 price objective for the company. Finally, Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $32.92.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company's stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Stock Performance

PFE stock traded up $0.52 during midday trading on Friday, reaching $25.65. The company had a trading volume of 41,896,988 shares, compared to its average volume of 54,672,200. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $28.21 and a 200 day moving average price of $28.57. The firm has a market capitalization of $145.36 billion, a PE ratio of 34.64, a P/E/G ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company earned ($0.17) earnings per share. The firm's revenue for the quarter was up 31.2% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's dividend payout ratio (DPR) is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.